11. Salvage Therapy for Acute Myeloid Leukemia: Current Strategies and Emerging Therapies

  1. Stefan Faderl MD Associate Professor and
  2. Hagop Kantarjian MD Chairman Professor
  1. Keith W. Pratz MD Assistant Professor of Oncology and
  2. Judith E. Karp MD Professor of Oncology and Medicine Director

Published Online: 4 JAN 2011

DOI: 10.1002/9781444327359.ch11

Leukemias: Principles and Practice of Therapy

Leukemias: Principles and Practice of Therapy

How to Cite

Pratz, K. W. and Karp, J. E. (2010) Salvage Therapy for Acute Myeloid Leukemia: Current Strategies and Emerging Therapies, in Leukemias: Principles and Practice of Therapy (eds S. Faderl and H. Kantarjian), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444327359.ch11

Editor Information

  1. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Author Information

  1. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA

Publication History

  1. Published Online: 4 JAN 2011
  2. Published Print: 26 NOV 2010

ISBN Information

Print ISBN: 9781405182355

Online ISBN: 9781444327359

SEARCH

Keywords:

  • acute myelogenous leukemia;
  • salvage therapy;
  • cell cycle;
  • signal transduction;
  • epigenetics;
  • immunomodulation

Summary

Acute myeloid leukemia (AML) will require salvage therapy in the majority of adult cases. Chemoresistance inherent to relapsed AML has left conventional chemotherapy as an unsatisfactory therapeutic option for many patients. Emerging therapies directed at novel cellular and microenvironmental pathways, including tyrosine kinases, epigenetic alterations, growth factor pathways and tumor-specific immunotherapies, are currently under development. Incorporation of novel therapeutics into chemotherapeutic regimens is ongoing, and all patients with relapsed or refractory AML should be considered for clinical trials.